2012. Continued international expansion according to plan. Strengthened market position through more partners and a broader product portfolio.
2011. Celebration of ten years as a trading company and delivery of the thousandth analyzer.
2010. CellaVision continues its expansion and shows continued profitability. A new distribution strategy laid the foundation for the next phase of growth, and the CellaVision share was listed on NASDAQ OMX Stockholm, Small Cap.
2007-2009. CellaVision presented positive results for the first time in 2007. The same year the company was listed on First North, and a subsidiary was established in Canada. The following year the Japanese subsidiary was set up and the product range was expanded with an application for Body Fluids. In 2009 CellaVision continued its geographical expansion and launched the third generation analyzer, the CellaVision® DM1200.
2000-2006. The first system of blood cell analysis, the Diffmaster® was launched in Europe the year of 2000. The product was cleared by the FDA in 2001 and a subsidiary was subsequently established in the USA. During the following years, distribution agreements were entered covering Europe and the US, the second generation products – the CellaVision® DM96 and CellaVision® DM8 – were developed and launched, and the client base expanded.
1994–1999. CellaVision was founded in 1994 in Lund, Sweden, with the intentions of developing automated microscopy analysis. The idea originated from Christer Fåhraeus, at the time a doctoral student of Neurophysiology at Lunds University. Fåhraeus was the CEO of the company up until 1998 when the present CEO Yvonne Mårtensson took over the post.